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ABSTRACT
Background Unprecedented workflow shifts during the 
coronavirus disease 2019 (COVID-19) pandemic have 
contributed to delays in acute care delivery, but whether 
it adversely affected endovascular thrombectomy metrics 
in acute large vessel occlusion (LVO) is unknown.
Methods We performed a retrospective review of 
observational data from 14 comprehensive stroke centers 
in nine US states with acute LVO. EVT metrics were 
compared between March to July 2019 against March 
to July 2020 (primary analysis), and between state- 
specific pre- peak and peak COVID-19 months (secondary 
analysis), with multivariable adjustment.
Results Of the 1364 patients included in the primary 
analysis (51% female, median NIHSS 14 [IQR 7–21], and 
74% of whom underwent EVT), there was no difference 
in the primary outcome of door- to- puncture (DTP) time 
between the 2019 control period and the COVID-19 
period (median 71 vs 67 min, P=0.10). After adjustment 
for variables associated with faster DTP, and clustering 
by site, there remained a trend toward shorter DTP 
during the pandemic (βadj=-73.2, 95% CI −153.8–7.4, 
Pp=0.07). There was no difference in DTP times 
according to local COVID-19 peaks vs pre- peak months 
in unadjusted or adjusted multivariable regression 
(βadj=-3.85, 95% CI −36.9–29.2, P=0.80). In this final 
multivariable model (secondary analysis), faster DTP 
times were significantly associated with transfer from 
an outside institution (βadj=-46.44, 95% CI −62.8 to – 
-30.0, P<0.01) and higher NIHSS (βadj=-2.15, 95% CI 
−4.2to – -0.1, P=0.05).
Conclusions In this multi- center study, there was no 
delay in EVT among patients treated for intracranial 
occlusion during the COVID-19 era compared with the 
pre- COVID era.
BACKGROUND
Coronavirus disease 2019 (COVID-19) has 
placed unprecedented stress on the US healthcare 
system. Delays in the evaluation of acute stroke 
and treatment with intravenous thrombolytics 
during the COVID-19 pandemic have been previ-
ously demonstrated.1–3 However, little has been 
reported in regard to patients harboring intra-
cranial occlusions who undergo endovascular 
thrombectomy (EVT).4 5 Guidelines during the 
COVID-19 pandemic have called for streamlined 
and efficient processes,6–11 however, there remain 
considerable variations in management paradigms 
with ongoing debates, including recommendations 
for pre- thrombectomy airway management, intra-
venous thrombolysis, and antithrombotics.12 Due 
to the enforcement of contact precautions, the 
use of personal protective equipment, and decon-
tamination procedures for imaging and treatment 
facilities, it stands to reason that the COVID-19 
pandemic may result in delays of acute interven-
tions for stroke. Furthermore, delays in acute care 
may also be affected by local surges in COVID-19 
cases as healthcare systems become overrun and 
resources exhausted.13 14]
The aim of the present study was to evaluate the 
impact of COVID-19 on the emergent management 
of acute intracranial occlusions. We hypothesized 
that the COVID-19 pandemic would lead to a delay 
in EVT time metrics, similar to the delay we have 
shown among patients treated with intravenous 
thrombolysis.1
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request, after clearance by the local ethics 
committee.
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Study population
We conducted a retrospective review of our prospectively main-
tained observational registry data to identify all consecutive 
patients with acute ischemic stroke and intracranial occlusion 
who underwent emergent angiography and/or thrombectomy at 
14 Comprehensive Stroke Centers (CSCs) across nine US states 
between January 1, 2019 and July 31, 2020. At the time of data 
consolidation, these states accounted for 47% of all reported US 
cases of COVID-19 and 37% of COVID-19- associated deaths.15 
Participating registry centers were recruited based on their affili-
ation with the Society of Vascular and Interventional Neurology.
Patients were eligible for inclusion if they experienced an 
acute intracranial occlusion of the internal carotid artery (ICA), 
middle cerebral artery (inclusive of M1, M2, or M3 segments), 
or vertebral and/or basilar arteries. Occlusion location was deter-
mined by CT angiography or by digital subtraction angiography. 
Patients were excluded if they were triaged by a mobile stroke 
unit (with these data being reported separately), if the stroke 
occurred while hospitalized (in- hospital stroke) given unique 
triage protocols associated with patient populations, and if they 
were admitted outside the study periods as outlined below.
Study periods
To maximize sensitivity for detecting differences in treatment 
times based on the differential burden and delayed spread of the 
novel coronavirus among the included sites, two analyses were 
performed. In the primary analysis, patients admitted between 
March 1, 2019 and July 31, 2019 (seasonal control period) were 
compared against patients admitted between March 1, 2020 and 
July 21, 2020 (COVID-19 period) across all sites. A secondary 
analysis was conducted based on relative COVID-19 surges 
affecting sites on the state level, according to data published by 
the New York Times.16 In this analysis, patients were compared 
between two contemporaneous months around the time of the 
first local COVID-19 “peak”. Months were selected for state- 
specific COVID-19 peak comparisons using a modified Delphi 
consensus between first, second, and senior authors (ALC, AMZ, 
JES) using qualitative visualization of new daily COVID-19 diag-
noses and total COVID-19 hospitalizations in that state.16 In this 
analysis, the month of the first clinically significant increase in 
daily COVID-19 diagnoses and/or hospitalizations was catego-
rized as the COVID-19 peak. To maximize sensitivity of the state- 
specific COVID-19 peak comparisons, the pre- peak (referent) 
period preceded the COVID-19 peak period by 1 month. For 
example, if the COVID-19 peak occurred in May 2020, the 
referent month would be March 2020 for that state. In this anal-
ysis, only the time of the first peak was used and only months 
through July 2020 could be selected as COVID-19 peak months 
due to the recent nature of multicenter data consolidation. For 
states in which new daily COVID-19 diagnoses did not have a 
clear peak (eg, Iowa), the peak of COVID-19 hospitalizations 
was used as the primary indicator of COVID-19 peak.
Variables and outcomes
Baseline demographic data including age (which was binned by 
decade to protect personal health information), sex, race, and 
ethnicity, as well as key vascular risk factors were collected from 
participating sites. Patient arrival method (use of emergency 
medical services (EMS) vs walk- in/private vehicle vs transfer 
from outside hospital), baseline stroke severity according to the 
National Institutes of Health Stroke Scale (NIHSS), occlusion 
location, and treatment with intravenous thrombolysis and/or 
EVT are also reported. To account for site EVT volume as a 
confounder, we included a variable recognizing sites as ‘high- 
volume’ if the 2019 EVT volume exceeded 50, in accordance 
with previously published data indicating faster treatment 
times.1 17
The primary outcome was door- to- puncture time, assessed as 
a continuous variable. We further explored the time windows 
from last known well (LKW) to arrival at the CSC, door to initial 
imaging, puncture to first pass, puncture to recanalization (or 
completion of angiography if recanalization unsuccessful), and 
overall LKW to recanalization. Additional endpoints included 
successful recanalization (defined as a thrombolysis in cere-
bral infarction (TICI) score of 2b/3) and discharge disposition 
(stratified by home, acute inpatient rehabilitation, other facility, 
or hospice/death which was consolidated). Due to the incom-
pleteness of data regarding discharge mRS scores (48% comple-
tion rate) and lack of available 90- day mRS scores for recently 
discharged patients from the COVID-19 pandemic, functional 
and long- term outcomes are not reported.
Statistical analysis
Categorical variables are reported using absolute counts and 
proportions, while non- normally distributed continuous vari-
ables are reported using medians and interquartile ranges 
(IQRs). Baseline characteristics between pre- COVID-19 and 
COVID-19 groups were compared using the Chi- square test or 
Fisher’s exact test for categorical variables, when appropriate, 
and the Wilcoxon rank- sum test for continuous variables. Unad-
justed logistic and linear regression models were generated to 
estimate the effect of the COVID-19 period on the primary 
and secondary outcomes of interest. An adjusted linear regres-
sion model was used to estimate the impact of the COVID-19 
period on any potential delay in the primary outcome of door- 
to- puncture time, with adjustment for all variables significant to 
P≤0.1 in univariate regression. Each adjusted regression model 
was clustered by site.
All statistical tests were 2- sided and conventional levels of 
significance (α=0.05) were used for interpretation, with P- values 
reported for conventional purposes only. Odds ratios and beta 
coefficients were reported with 95% confidence intervals (OR 
or β [95% CI]). No adjustments were made for multiple compar-
isons as analyses were exploratory and hypothesis- generating. 
Missing data were not imputed. STATA 15.0 (StataCorp, LLC) 
software was used for data analysis.
Ethics statement
The local institutional review board (Committee for the Protec-
tion of Human Subjects) at each participating center reviewed 
and approved the study with waiver of consent and HIPAA 
authorization was granted. This study is reported in accordance 




Of 12 187 patients screened from the multicenter registry, 6277 
patients were admitted within the study window for the primary 
analysis. Of these, 4868 were excluded due to lack of intracra-
nial occlusion, 26 for experiencing an in- hospital stroke, and 18 
due to initial evaluation in a mobile stroke unit, leaving 1364 
included in the primary analysis (online supplemental figure 1). 
More than half (51%) were ≥70 years of age, 48% were female, 
and 61% were White (table 1). The median NIHSS was 14 
(IQR 7–21), and 74% had an occlusion of the internal carotid, 
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proximal middle cerebral (M1), or basilar artery. There was a 
28% decrease in the total number of patients with any intra-
cranial occlusion during the COVID-19 period when compared 
with the 2019 seasonal control period (570 vs 794 patients). 
Compared with patients who presented in the seasonal control 
period, patients who presented in the COVID-19 period were 
more frequently Hispanic (OR 1.40, 95% CI 1.03 to 1.89, 
P=0.03), had coronary artery disease (OR 1.91, 95% CI 1.41 to 
2.58, P<0.01), and had a higher probability of undergoing EVT 
(OR 1.39, 95% CI 1.08 to 1.78, P=0.01).
For the primary outcome of door- to- puncture time, there 
was no significant difference in door- to- puncture times among 
patients admitted during the COVID-19 period vs the seasonal 
control period (β=−41.9, 95% CI −93.0–9.1, P=0.11; see 
table 2 for absolute time differences). After adjustment for all 
candidate variables associated with door- to- puncture (P<0.1: 
history of hypertension, diabetes, dyslipidemia, transfer from 
outside institution, and baseline NIHSS) and clustering by site, 
there was a trend toward faster door- to- puncture times during 
the COVID-19 period (βadj=-73.2, 95% CI −153.8–7.4, P=0.07; 
table 3). While transfer from an outside institution was signifi-
cantly associated with faster door- to- puncture time in univar-
iate regression (P=0.04), it was no longer associated with faster 
treatment in multivariable regression (padj=0.30). Only a history 
of hypertension was independently associated with delayed EVT 
during the COVID-19 period (βadj=57.1, 95% CI −1.3–115.5, 
P=0.05). A greater proportion of patients were discharged home 
over acute inpatient rehabilitation during the COVID-19 period 
when compared with the control period (38% vs 33%, P<0.01; 
table 2).
Secondary analysis
For the secondary analysis of state- specific COVID-19 peaks, 
there was 100% agreement among the three raters regarding 
each state’s first COVID-19 peak (figure 1). In this analysis, 123 
patients were admitted in the state- specific pre- peak month and 
84 patients were admitted during the state- specific COVID-19 
peak (32% decline during local COVID-19 peak). Compared 
with the pre- peak month, patients admitted during the local 
COVID-19 peak more frequently had atrial fibrillation (OR 
2.18, 95% CI 1.12 to 4.26, P=0.02) with a trend toward lower 
odds of prior stroke (OR 0.43, 95% CI 0.18 to 1.02, P=0.06). 
There was a higher prevalence of basilar occlusion during the 
COVID-19 peak (OR 5.41, 95% CI 1.44 to 20.28, P=0.01), but 
no other differences with respect to age, sex, or comorbidities 
(online supplemental table 1).
For the primary outcome of door- to- puncture, there was 
no significant difference in treatment times among patients 
admitted during the local COVID-19 peak vs the pre- peak month 
(β=2.29, 95% CI −23.9–28.5, P=0.86) and there remained no 
significant difference after adjustment for all candidate variables 
included in the multivariable regression model (P<0.1: White 
race, transfer from an outside institution, NIHSS, and occlusion 
of the ICA/M1/basilar artery), and after clustering by site (βadj=-
3.85, 95% CI −29.9–22.2, P=0.77; online supplemental table 
2). In this final multivariable model, faster door- to- puncture 
times were significantly associated with transfer from an outside 
institution (βadj=-46.44, 95% CI −62.8 to−30.0, P<0.01) and 
higher NIHSS (βadj=-2.15, 95% CI −4.2 to−0.1, P=0.05).
CONCLUSIONS
In this multicenter investigation evaluating treatment times of 
1364 patients with an acute intracranial occlusion across nine US 
states, we observed no significant delay in thrombectomy treat-
ment time during the COVID-19 pandemic. Our findings of a 
nearly one- third reduction in LVO incidence may be in part due 
to a reduction in patients seeking care during the pandemic,18 
rather than a reduction in LVO stroke incidence. The increased 
likelihood of EVT is not fully explained in the present analysis, 
and it may be related to patient- level factors and imaging find-
ings (eg, estimated infarct volume, collateral status, perfusion 
findings) which were not collected as part of this observational 









Age group, no. (%) 0.47
  <50 151 (11%) 93 (12%) 58 (10%)
  50–69 524 (38%) 310 (39%) 214 (38%)
  ≥70 689 (51%) 391 (49%) 298 (52%)
Female, no. (%) 649 (48%) 382 (48%) 267 (47%) 0.64
Hispanic, no. (%) 199/1,349 (15%) 102/786 (13%) 97/563 (17%) 0.03
Race, no. (%) 0.07
  White 827 (61%) 460 (58%) 367 (64%)
  Black 329 (24%) 198 (25%) 131 (23%)
  Asian 29 (2%) 19 (2%) 10 (2%)
  Other/unknown 179 (13%) 117 (15%) 62 (11%)
Medical history, 
no. (%)
  Hypertension 1021 (75%) 600 (76%) 421 (74%) 0.47
  Dyslipidemia 637 (47%) 359 (45%) 278 (49%) 0.19
  Diabetes 437 (32%) 245 (31%) 192 (34%) 0.27
  Atrial fibrillation 297 (22%) 174 (22%) 123 (22%) 0.88
  Tobacco use 256 (19%) 153 (19%) 103 (18%) 0.58
  Prior ischemic 
stroke
248 (18%) 135 (17%) 113 (20%) 0.18
  Coronary artery 
disease
204 (15%) 91 (11%) 113 (20%) <0.01
Arrival method, no. 
(%)
0.42
  EMS 416/1,245 (33%) 222/696 (32%) 194/549 (35%)
  Walk- in/private 
vehicle
85/1,245 (7%) 50/696 (7%) 35/549 (6%)
  Transfer 744/1,245 (60%) 424/696 (61%) 320/549 (58%)











180/1,124 (16%) 93/655 (14%) 87 (19%) 0.05
Site of occlusion, 
no. (%)
  ICA 327 (24%) 189 (24%) 138 (24%) 0.86
  MCA–M1 659 (48%) 381 (48%) 278 (49%) 0.77
  MCA–M2 317 (23%) 190 (24%) 127 (22%) 0.48
  MCA–M3 68 (5%) 44 (6%) 24 (4%) 0.27
  Basilar artery 86 (6%) 42 (5%) 44 (8%) 0.07
  Vertebral artery 55 (4%) 34 (4%) 21 (4%) 0.58
Thrombectomy, no. 
(%)
1003 (74%) 563 (71%) 440 (77%) <0.01
  Thrombectomy for 
ICA, M1, or basilar 
occlusions, no. (%)
789/1,003 (79%) 430/569 (76%) 359/434 (83%) <0.01
EMS, emergency medical services; ICA, internal carotid artery; IQR, interquartile range; MCA, 
middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale score.
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study. Declines in LVO rate during the COVID-19 period (and 
in the state- specific COVID-19 peaks) were not driven by any 
one particular center, as 11 sites observed the same effect (three 
sites had similar or higher case rates during COVID-19; data 
not otherwise shown). Furthermore, we observed a trend toward 
shorter door- to- puncture times during the COVID-19 period 
when compared with the 2019 seasonal control period. This 
may be related, at least in part, to the lower volume of elective 
angiographic and neurointerventional cases as part of the health-
care response to the pandemic,19 20 as well as the lower volume 
of emergent endovascular cases.21 The shorter time between 
arrival and angiography may also be related to the manner in 
which patients arrived to CSCs included in this analysis. More 
than half of patients were transferred from an outside institution 
(60% of cohort), and these individuals were generally treated 
with greater expediency when compared with non- transferred 
patients. Longer door- to- puncture delays during the COVID-19 
period were observed among included patients who arrived at 
the CSC using private transportation, which is unsurprising 
given prior experiences.22 23 Pre- hospital evaluation and notifica-
tion by EMS and external providers can expedite the prepared-
ness of the CSC interventional team and shorten delays from 
CSC arrival to skin puncture.24 25 While only a small proportion 
of patients included in this analysis presented by private vehicle/
walk- in (7% of cohort), the effect of private transport on EVT 
throughput is likely a significant underestimation of the national 
Table 2 Procedural and clinical outcomes of EVT by seasonal period
Outcomes Total (n=1364) March–July 2019 (n=794) March–July 2020 (n=570) P- value
Door- to- puncture, median min (IQR)
  Overall 70 (37–103) (n=982) 71 (41–104) (n=556) 67 (33–102) (n=426) 0.10
  Transfers 45 (24–80) (n=579) 47 (28–81) (n=309) 43 (22–80) (n=270) 0.25
  EMS 94 (73–123) (n=305) 94 (73–127) (n=167) 95 (73–118) (n=138) 0.56
  Private vehicle/walk- in 117 (84–209) (n=28) 106 (82–128) (n=19) 265 (168–319) (n=9) 0.04
LKW to CSC arrival, median min (IQR)
  Overall 335 (165–807) (n=1257) 345 (162–794) (n=736) 325 (170–839) (n=521) 0.81
  Transfers 406 (237–857) (n=707) 400 (227–837) (n=401) 412 (247–862) (n=306) 0.47
  EMS 146 (66–606) (n=385) 159 (68–642) (n=208) 138 (60–482) (n=177) 0.16
  Private vehicle/walk- in 683 (156–1622) (n=63) 589 (40–1280) (n=40) 813 (23–736) (n=23) 0.27
Door to imaging, median min (IQR)
  Overall 17 (10–33) (n=660) 17 (10–34) (n=357) 17 (11–33) (n=303) 0.87
  Transfers 18 (11–52) (n=143) 21 (12–97) (n=61) 16 (10–45) (n=82) 0.13
  EMS 15 (9–24) (n=375) 14 (9–24) (n=191) 17 (10–25) (n=184) 0.21
  Private vehicle/walk- in 32 (19–77) (n=64) 34 (18–71) (n=37) 30 (23–83) (n=27) 0.72
Puncture to first pass, median min (IQR)
  Overall 18 (12–29) (n=947) 19 (12–32) (n=529) 18 (12–26) (n=418) 0.04
  Transfers 19 (13–28) (n=560) 19 (13–31) (n=294) 18 (13–26) (n=266) 0.22
  EMS 18 (10–30) (n=289) 20 (10–35) (n=155) 17 (10–27) (n=134) 0.10
  Private vehicle/walk- in 23 (13–33) (n=25) 19 (12–33) (n=19) 29 (16–41) (n=6) 0.36
Puncture to recanalization, median min (IQR)
  Overall 33 (21–56) (n=882) 34 (21–57) (n=497) 32 (20–53) (n=385) 0.33
  Transfers 33 (21–53) (n=527) 33 (22–57) (n=282) 32 (20–49) (n=245) 0.31
  EMS 34 (21–57) (n=275) 37 (23–60) (n=151) 32 (20–55) (n=124) 0.24
  Private vehicle/walk- in 43 (25–84) (n=21) 37 (23–75) (n=14) 91 (38–103) (n=7) 0.07
LKW to recanalization, median min (IQR)
  Overall 431 (260–832) (n=844) 434 (255–816) (n=475) 425 (265–854) (n=369) 0.93
  Transfers 499 (313–906) (n=510) 455 (297–841) (n=274) 525 (327–923) (n=236) 0.26
  EMS 284 (193–711) (n=267) 331 (206–783) (n=145) 264 (188–592) (n=122) 0.04
  Private vehicle/walk- in 748 (494–1187) (n=20) 624 (339–856) (n=14) 1169 (744–1918) (n=6) 0.08
TICI 2b/3 recanalization, no. (%) 917/979 (94%) 509/551 (92%) 408/428 (95%) 0.06
Discharge disposition, no. (%) <0.01
  Home 479/1,361 (35%) 262 794 (33%) 217/567 (38%)
  Acute rehabilitation 227/1,361 (17%) 158/794 (20%) 69/567 (12%)
  Skilled nursing facility/LTAC/unspecified facility 401/1,361 (29%) 241/794 (30%) 160/567 (28%)
  Hospice/death 254/1,361 (19%) 133/794 (17%) 121/567 (21%)
CSC, Comprehensive Stroke Center; EMS, emergency medical services; IQR, interquartile range; LKW, last known well; LTAC, long- term acute care facility; TICI, thrombolysis in 
cerebral infarction.
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(and international) experience. This study was limited to the 
experience of CSCs which are vastly outnumbered by Primary 
Stroke Centers, urgent care facilities, and community hospitals 
where these patients may initially present. Therefore, we would 
continue to encourage patients to call for emergency services in 
the event of a sudden, significant neurologic symptom. Earlier 
symptom recognition in the field and at non- CSCs can expedite 
reperfusion therapies.
Regarding other time metrics in the acute care of patients 
with intracranial occlusion, we found no significant delay in 
arrival to first head imaging at participating CSCs. Presum-
ably, any delay in the acute care of patients treated in the 
emergency department during the COVID-19 pandemic 
would relate to initial triage as providers are committing 
more time and attention to contact precautions, hygiene, 
and decontamination. However, there appeared to be no 
difference in time from CSC arrival to first head imaging 
between patients admitted during COVID-19 vs the 2019 
seasonal control period (or among patients admitted during 
local COVID-19 peaks vs the preceding period). In a related 
study, we found a small but significant 8- min decrease in 
arrival to first head imaging among patients evaluated 
during the COVID-19 pandemic, including patients without 
an intracranial occlusion (median 29 vs 37 min, P<0.01).1 
It is possible that faster imaging times may not have been 
observed in this cohort due to its smaller sample size or 
more restrictive inclusion criteria.
Unsurprisingly, patients who were transferred from an 
outside hospital with an acute ischemic stroke had faster 
treatment times. In the primary analysis, shorter door- to- 
puncture times among patients transferred vs those who 
arrived initially at the CSC was no longer significant after 
adjustment for measurable confounders. However, when 
state- specific COVID-19 peaks were evaluated, there 
remained a strong and independent relationship between 
transfer status and shorter door- to- puncture times.
Of note, there was a significant difference in discharge 
disposition among hospitalized patients during COVID-19 
when compared with the seasonal control. This is likely 
mediated by several indirect effects of the pandemic. First, 
patients admitted during COVID-19 typically have more 
severe disease and more comorbidities, as we have shown in 
an overlapping cohort.26 Therefore, the in- hospital mortality 
risk would be expectedly higher in this population. Second, 
unprecedented depletion of acute care beds to manage 
patients with COVID-19 has been met with a commensurate 
decrease in available inpatient rehabilitation and nursing 
beds for discharge- eligible patients.27 In order to safely and 
efficiently discharge patients with stroke and other medical 
diseases, many patients have been (and are being) discharged 
to home with home or outpatient services, and close neuro-
medical follow- up. It is possible that a small proportion of 
these patients would have otherwise benefited from more 
aggressive inpatient rehabilitation, however constraints on 
medical infrastructure have demanded creative, patient- level 
responses during this pandemic.28 29
Our investigation is unique in that we conducted an 
analysis that accounted for the first local COVID-19 peak 
in each state. As shown in figure 1, several states (notably 
California, Florida, Georgia, Ohio, and Texas) experienced 
delayed surges in COVID-19 cases. Therefore, an analysis 
limited to the first few months of the pandemic in the US 
might have been too early to detect any impact of COVID-19 
surges on treatment times in these regions. In this secondary 
analysis–while the sample size was lower than that of the 
primary analysis–there was still no statistically or clinically 
significant difference in treatment times between pre- peak 
and peak periods.
Limitations
While this study is the largest pooled data set reflecting 
multiple unique regions in the US affected by the COVID-19 
Table 3 Candidate variables associated with door- to- puncture time in the primary analysis
Candidate variable β (95% CI) P- value βadj (95% CI) P- value
  Admission during COVID-19 period −41.9 (-93.0 to 9.1) 0.11 −73.2 (-153.8 to 7.4) 0.07
  Age (per tertile) −3.0 (-39.7 to 33.8) 0.88
  Female 9.0 (-41.7 to 59.7) 0.73
  Hispanic 59.5 (-19.3 to 138.4) 0.14
  White 17.3 (-34.5 to 69.2) 0.51
  Hypertension 52.6 (-4.8 to 110.0) 0.07 57.1 (-1.3 to 115.5) 0.05
  Dyslipidemia 53.2 (2.1 to 104.3) 0.04 22.8 (-39.2 to 84.7) 0.44
  Diabetes 47.2 (-8.0 to 102.5) 0.09 32.3 (-36.6 to 101.1) 0.33
  Atrial fibrillation 9.8 (-51.4 to 70.9) 0.75
  Tobacco use 49.3 (-14.8 to 113.3) 0.13
  Prior ischemic stroke 26.0 (-39.4 to 91.4) 0.44
  Coronary artery disease 32.7 (-43.7 to 109.2) 0.40
  Transfer vs direct CSC arrival −55.1 (-107.6 to -2.6) 0.04 −40.4 (-122.2 to 41.3) 0.30
  High- volume center* 13.5 (-40.3 to 67.4) 0.62
  NIHSS (per point) −7.2 (-11.6 to -2.8) <0.01 −5.9 (-13.9 to 2.1) 0.13
  Intravenous thrombolysis 24.0 (-170.6 to 122.5) 0.75
  ICA, M1, or basilar occlusion −26.0 (-87.6 to 35.7) 0.41
Variables were included in the final multivariable model if they were significant to P<0.1 in unadjusted regression. The final multivariable model was clustered by site.
*A high- volume stroke center was defined as having performed 50 or more thrombectomies during 2019, as this volume threshold has been shown to improve treatment times.
CI, confidence interval; COVID-19, coronavirus disease 2019; EMS, emergency medical services; ICA, internal carotid artery; NIHSS, National Institutes of Health Stroke Scale.
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pandemic, it is limited by its retrospective and explor-
atory nature. The brief study periods and small sample size 
included in the primary and secondary analyses may have 
contributed to a type II error. Certain data elements, such 
as vital signs on admission and variables related to social 
history or emergency department volume, may have also 
contributed to delays in endovascular treatment times, but 
these data were not available from the consolidated prospec-
tive registries. In spite of these limitations, we still believe 
there to be no clinically significant delay in EVT as a conse-
quence of the pandemic. If anything, there appeared to 
be a trend toward shorter arrival to EVT times during the 
COVID-19 pandemic when compared with identical months 
in the preceding year (padj=0.07).
The lack of available long- term outcome data in the 
present analysis, and lack of adjustment for COVID-19 
infection status among included patients are other shortcom-
ings of this study. However, as we have previously shown 
using data that overlaps with this registry,30 the prevalence 
of ischemic stroke in patients with COVID-19 was 1.1%–
1.4% with approximately half of these patients harboring 
an intracranial occlusion. Although COVID-19- associated 
stroke is typically more severe, this low prevalence is unlikely 
to significantly confound the results of this investigation. 
Due to the recency of data consolidation for this analysis, 
long- term follow- up data remain unavailable. That said, the 
impact of delays in door- to- puncture have been extensively 
described in relation to long- term functional outcomes.31
In this multi- center observational registry representing the 
experience at 14 CSCs in nine US states, which accounted 
for nearly half of all reported COVID-19 cases during the 
early wave of the pandemic, we found no significant delay 
in thrombectomy among patients with acute intracranial 
occlusion. While the number of new LVO cases fell consid-
erably, the proportion of thrombectomies increased among 
all intracranial occlusions, and among patients with prox-
imal occlusions. While patients with mild strokes may be 
avoidant of the hospital,26 further research is called upon to 
explore potential reasons for the decline in new LVOs. The 
majority of patients in this analysis were transferred from 
an outside institution to the CSC, and in general, treatment 
times were quicker for these patients when compared with 
Figure 1 State- specific COVID-19 peak and pre- peak periods for secondary analysis. April 2020 was selected as the month of the first COVID-19 
peak for New Jersey (n=2 sites), Pennsylvania (n=2 sites), and Massachusetts (n=1 site); May 2020 as the first COVID-19 peak for Iowa (n=1 site); and 
July 2020 the first COVID-19 peak for Texas (n=2 sites), Ohio (n=2 sites), Georgia (n=2 sites), Florida (n=1 site), and California (n=1 site). COVID-19 
denotes coronavirus disease 2019.
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patients who presented via EMS or private vehicle. Treat-
ment times remained significantly and independently shorter 
among patients who were transferred in the secondary anal-
ysis evaluating local COVID-19 peaks. Slower treatment 
among patients who present directly to CSC emergency 
departments remains a potential gap for the improvement in 
the care of patients with acute stroke. Centers are encour-
aged to evaluate their local paradigms for opportunities to 
facilitate the throughput of patients who arrive directly to 
their emergency department with stroke due to intracranial 
occlusion.
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